Home » Oncologists: Classwide ESA REMS Equals Administrative Burden
Oncologists: Classwide ESA REMS Equals Administrative Burden
The American Society of Clinical Oncology
is drafting a letter to the FDA citing concerns that the society was excluded from the agency’s
development of a classwide risk evaluation and mitigation strategy (REMS). The letter is related to a REMS for Amgen’s three erythropoiesis-stimulating
agents (ESAs) that took effect March 24.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May